Anil K Sood

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9212491/anil-k-sood-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

333 papers	26,510 citations	75 h-index	157 g-index
391 ext. papers	31,590 ext. citations	9.1 avg, IF	6.83 L-index

#	Paper	IF	Citations
333	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.. *Cancer and Metastasis Reviews*, **2022**, 41, 147	9.6	2
332	Targeting CCR2 macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.. *Journal of Cancer Research and Clinical Oncology*, **2022**, 148, 803	4.9	0
331	Endothelial p130cas confers resistance to anti-angiogenesis therapy.. *Cell Reports*, **2022**, 38, 110301	10.6	2
330	Race-associated Molecular Changes in Gynecologic Malignancies. *Cancer Research Communications*, **2022**, 2, 99-109		0
329	Spatially resolved transcriptomics of high-grade serous ovarian carcinoma.. *IScience*, **2022**, 25, 103923	6.1	1
328	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. *Cancers*, **2022**, 14, 2498	6.6	1
327	RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. *Cell Reports*, **2021**, 37, 109934	10.6	4
326	Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. *International Journal of Gynecological Cancer*, **2021**, 31, 232-237	3.5	
325	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. *International Journal of Gynecological Cancer*, **2021**, 31, 92-97	3.5	1
324	The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. *Seminars in Cancer Biology*, **2021**,	12.7	2
323	Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study. *BMC Womens Health*, **2021**, 21, 376	2.9	
322	Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. *Gynecologic Oncology*, **2021**, 160, 777-785	4.9	5
321	Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. *Oncogene*, **2021**, 40, 3533-3547	9.2	24
320	The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. *Blood Advances*, **2021**, 5, 1947-1951	7.8	3
319	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. *Gynecologic Oncology*, **2021**, 161, 104-112	4.9	2
318	Chronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients. *Psycho-Oncology*, **2021**, 30, 954-961	3.9	0
317	Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. *Gynecologic Oncology*, **2021**, 161, 56-62	4.9	0

316	CD8 T cells inhibit metastasis and CXCL4 regulates its function. *British Journal of Cancer*, **2021**, 125, 176-189	8.7	3
315	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. *Scientific Reports*, **2021**, 11, 9362	4.9	3
314	Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment. *Psychosomatic Medicine*, **2021**, 83, 417-422	3.7	3
313	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. *Carcinogenesis*, **2021**, 42, 785-793	4.6	1
312	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. *IScience*, **2021**, 24, 102757	6.1	3
311	Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. *Scientific Reports*, **2021**, 11, 11595	4.9	4
310	Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecologic Oncology*, **2021**, 161, 660-667	4.9	1
309	Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. *Science Advances*, **2021**, 7,	14.3	7
308	The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. *Oncogene*, **2021**, 40, 384-395	9.2	7
307	Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. *Clinical Cancer Research*, **2021**, 27, 542-553	12.9	6
306	Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. *Gynecologic Oncology*, **2021**, 160, 586-601	4.9	18
305	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. *Gynecologic Oncology*, **2021**, 160, 32-39	4.9	3
304	Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. *Methods in Molecular Biology*, **2021**, 2372, 157-168	1.4	
303	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. *Investigational New Drugs*, **2021**, 39, 829-835	4.3	3
302	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. *Cell Reports*, **2021**, 34, 108726	10.6	8
301	Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. *IScience*, **2021**, 24, 102053	6.1	1
300	Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. *Cancers*, **2021**, 13,	6.6	5
299	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3

298	A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. *Cancers*, **2021**, 13,	6.6	1
297	Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. *Human Pathology*, **2021**, 113, 20-27	3.7	3
296	The Provocative Roles of Platelets in Liver Disease and Cancer. *Frontiers in Oncology*, **2021**, 11, 643815	5.3	1
295	Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. *Gynecologic Oncology*, **2021**, 162, 65-71	4.9	0
294	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. *Gynecologic Oncology*, **2021**, 163, 181-190	4.9	0
293	Gene Body Methylation of the Lymphocyte-Specific Gene Results in Its Overexpression and Regulates Cancer mTOR Signaling. *Molecular Cancer Research*, **2021**, 19, 1917-1928	6.6	2
292	Rural residence is related to shorter survival in epithelial ovarian cancer patients. *Gynecologic Oncology*, **2021**, 163, 22-28	4.9	1
291	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. *Cell Reports*, **2021**, 36, 109549	10.6	2
290	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. *Gynecologic Oncology*, **2021**, 162, 482-495	4.9	4
289	Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates. *Nature Communications*, **2021**, 12, 5410	17.4	10
288	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. *Oncogenesis*, **2021**, 10, 65	6.6	3
287	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 3545-3555	4.9	1
286	Antihypertensive medication use and ovarian cancer survival. *Gynecologic Oncology*, **2021**, 163, 342-347	4.9	0
285	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. *Clinical Cancer Research*, **2021**, 27, 6354-6365	12.9	5
284	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. *Molecular Cancer Therapeutics*, **2021**, 20, 2352-2361	6.1	0
283	Retraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. *Nature*, **2020**, 582, 134	50.4	5
282	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. *Gynecologic Oncology*, **2020**, 158, 59-65	4.9	9
281	Role of Micro-RNA for Pain After Surgery: Narrative Review of Animal and Human Studies. *Anesthesia and Analgesia*, **2020**, 130, 1638-1652	3.9	5

280	Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review. *Cancers*, **2020**, 12,	6.6	9
279	NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. *Molecular Cancer Therapeutics*, **2020**, 19, 1727-1735	6.1	2
278	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. *JAMA Oncology*, **2020**, 6, 1110-1113	13.4	14
277	Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. *Cancer*, **2020**, 126, 2607-2613	6.4	8
276	Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2020**, 25, 102169	6	8
275	Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. *Scientific Reports*, **2020**, 10, 520	4.9	4
274	Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. *Gynecologic Oncology*, **2020**, 157, 386-391	4.9	14
273	Evolving population-based statistics for rare epithelial ovarian cancers. *Gynecologic Oncology*, **2020**, 157, 3-11	4.9	5
272	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. *Gynecologic Oncology*, **2020**, 157, 21-28	4.9	3
271	Low-grade serous ovarian cancer: State of the science. *Gynecologic Oncology*, **2020**, 156, 715-725	4.9	28
270	Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. *Oncotarget*, **2020**, 11, 2819-2833	3.3	2
269	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. *Cellular Signalling*, **2020**, 68, 109539	4.9	32
268	Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms. *Brain, Behavior, and Immunity*, **2020**, 87, 860-880	16.6	1
267	Pan-cancer clinical and molecular analysis of racial disparities. *Cancer*, **2020**, 126, 800-807	6.4	15
266	A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer. *Clinical Cancer Research*, **2020**, 26, 9-10	12.9	1
265	Predictors of survival trajectories among women with epithelial ovarian cancer. *Gynecologic Oncology*, **2020**, 156, 459-466	4.9	11
264	Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. *RNA Biology*, **2020**, 17, 1523-1534	4.8	9
263	Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. *IScience*, **2020**, 23, 101289	6.1	5

262	Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. *Cancer*, **2020**, 126, 4407-4413	6.4	5
261	Characterization of and isolation methods for plant leaf nanovesicles and small extracellular vesicles. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2020**, 29, 102271	6	12
260	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. *Gynecologic Oncology*, **2020**, 158, 653-658	4.9	4
259	Targeting progesterone signaling prevents metastatic ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 31993-32004	11.5	9
258	OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. *Blood Advances*, **2020**, 4, 3329-3342	7.8	12
257	Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 1943-1954	6.1	3
256	Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 2396-2406	6.1	4
255	Clinical and biological significance of expression in endometrial cancer. *Cancer Biology and Therapy*, **2020**, 21, 147-156	4.6	10
254	Placenta-derived extracellular vesicles induce preeclampsia in mouse models. *Haematologica*, **2020**, 105, 1686-1694	6.6	31
253	Significance of lymph node ratio on survival of women with borderline ovarian tumors. *Archives of Gynecology and Obstetrics*, **2020**, 301, 1289-1298	2.5	5
252	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. *Cell Reports*, **2020**, 31, 107502	10.6	28
251	Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. *Bioconjugate Chemistry*, **2019**, 30, 2675-2683	6.3	32
250	PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. *EBioMedicine*, **2019**, 40, 290-304	8.8	20
249	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. *Oncotarget*, **2019**, 10, 3533-3546	3.3	12
248	Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. *Cancer*, **2019**, 125, 2409-2422	6.4	11
247	Pan-cancer genomic analysis links 3′UTR DNA methylation with increased gene expression in T cells. *EBioMedicine*, **2019**, 43, 127-137	8.8	18
246	Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. *Oncogene*, **2019**, 38, 5191-5210	9.2	10
245	Circular RNAs in Cancer. *Molecular Therapy - Nucleic Acids*, **2019**, 16, 118-129	10.7	225

244	GnRH-R-Targeted Lytic Peptide Sensitizes Wild-type Ovarian Cancer to PARP Inhibition. *Molecular Cancer Therapeutics*, **2019**, 18, 969-979	6.1	9
243	exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. *Cell*, **2019**, 177, 463-477.e15	56.2	144
242	Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. *Cell*, **2019**, 177, 446-462.e16	56.2	142
241	Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. *Psychoneuroendocrinology*, **2019**, 106, 244-251	5	7
240	Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. *Clinical Chemistry*, **2019**, 65, 674-683	5.5	48
239	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. *Scientific Reports*, **2019**, 9, 11153	4.9	22
238	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. *Oncogene*, **2019**, 38, 6095-6108	6.8	29
237	Chromosomal Instability in Tumor Initiation and Development. *Cancer Research*, **2019**, 79, 3995-4002	10.1	27
236	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. *Gynecologic Oncology*, **2019**, 154, 524-530	4.9	13
235	Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. *Gynecologic Oncology*, **2019**, 153, 230-237	4.9	11
234	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. *Clinical Cancer Research*, **2019**, 25, 5702-5716	12.9	14
233	Mechanisms of nuclear content loading to exosomes. *Science Advances*, **2019**, 5, eaax8849	14.3	98
232	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. *Cell Reports*, **2019**, 29, 4389-4406.e10	10.6	36
231	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. *Scientific Reports*, **2019**, 9, 17589	4.9	7
230	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. *Genome Biology*, **2019**, 20, 253	18.3	9
229	Exploring and comparing adverse events between PARP inhibitors. *Lancet Oncology, The*, **2019**, 20, e15-e28	28.7	138
228	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. *Cancer Letters*, **2019**, 442, 464-474	9.9	38
227	EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. *Oncogene*, **2019**, 38, 2123-2134	9.2	16

226	Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. *Gynecologic Oncology*, **2019**, 152, 101-105	4.9	11
225	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. *Molecular Cancer Therapeutics*, **2019**, 18, 421-436	6.1	7
224	/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. *Molecular Cancer Therapeutics*, **2019**, 18, 162-172	6.1	11
223	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. *Cell Reports*, **2018**, 23, 823-837	10.6	22
222	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. *Cancer Research*, **2018**, 78, 3233-3242	10.1	46
221	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Reports*, **2018**, 23, 297-312.e12	10.6	147
220	The Platelet Lifeline to Cancer: Challenges and Opportunities. *Cancer Cell*, **2018**, 33, 965-983	24.3	202
219	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. *Nature Communications*, **2018**, 9, 476	17.4	31
218	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. *Nature Communications*, **2018**, 9, 461	17.4	39
217	LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. *Cancer Research*, **2018**, 78, 1923-1934	10.1	42
216	Isolation of Extracellular RNA from Serum/Plasma. *Methods in Molecular Biology*, **2018**, 1740, 43-57	1.4	6
215	HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. *Stem Cell Reports*, **2018**, 10, 212-227	8	32
214	Association of biobehavioral factors with non-coding RNAs in cervical cancer. *BioScience Trends*, **2018**, 12, 24-31	9.9	3
213	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*, **2018** , 33, 690-705.e9	24.3	277
212	The role of long noncoding RNAs in cancer: the dark matter matters. *Current Opinion in Genetics and Development*, **2018**, 48, 8-15	4.9	96
211	FABP4 as a key determinant of metastatic potential of ovarian cancer. *Nature Communications*, **2018**, 9, 2923	17.4	82
210	Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. *Frontiers in Cardiovascular Medicine*, **2018**, 5, 23	5.4	9
209	Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. *Therapeutic Advances in Medical Oncology*, **2018**, 10, 1758835918778483	5.4	15

208	CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. *Cancer Research*, **2018**, 78, 6247-6256	10.1	53
207	Bioactive lipid metabolism in platelet "first responder" and cancer biology. *Cancer and Metastasis Reviews*, **2018**, 37, 439-454	9.6	13
206	Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. *Cancer*, **2018**, 124, 3401-3408	6.4	10
205	Stress, inflammation, and eicosanoids: an emerging perspective. *Cancer and Metastasis Reviews*, **2018**, 37, 203-211	9.6	31
204	Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. *Drug Delivery*, **2018**, 25, 1394-1402	7	36
203	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. *JCI Insight*, **2018**, 3,	9.9	2
202	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. *Journal of Clinical Investigation*, **2018**, 128, 589-606	15.9	71
201	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. *Oncotarget*, **2018**, 9, 25115-25126	5.3	13
200	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. *Cancer Research*, **2018**, 78, 64-74	10.1	76
199	Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. *Molecular and Cellular Neurosciences*, **2018**, 86, 65-71	4.8	27
198	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 464-473	6.1	3
197	RNA interference-based therapy and its delivery systems. *Cancer and Metastasis Reviews*, **2018**, 37, 107-124	9.6	120
196	Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. *Cancer*, **2018**, 124, 580-586	6.4	21
195	Aspirin use and endometrial cancer risk and survival. *Gynecologic Oncology*, **2018**, 148, 222-232	4.9	27
194	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. *EBioMedicine*, **2018**, 38, 100-112	8.8	100
193	The role of tumor microenvironment in resistance to anti-angiogenic therapy. *F1000Research*, **2018**, 7, 326	3.6	34
192	Bone protection by inhibition of microRNA-182. *Nature Communications*, **2018**, 9, 4108	17.4	45
191	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. *Cancer Cell*, **2018**, 34, 549-560.e9	24.3	78

190	Trends of low-grade serous ovarian carcinoma in the United States. *Journal of Gynecologic Oncology*, **2018**, 29, e15	4	19
189	Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. *Gynecologic Oncology*, **2018**, 151, 428-432	4.9	12
188	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. *Gynecologic Oncology*, **2018**, 151, 374-380	4.9	0
187	Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. *Brain, Behavior, and Immunity*, **2018**, 73, 294-309	16.6	40
186	Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. *JAMA Oncology*, **2018**, 4, 1519-1526	13.4	17
185	Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress. *Biochemical Journal*, **2017**, 474, 731-749	3.8	40
184	Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. *Gynecologic Oncology*, **2017**, 144, 496-502	4.9	21
183	Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 966-976	6.1	31
182	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). *Molecular Cancer Therapeutics*, **2017**, 16, 1114-1123	6.1	61
181	Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. *Genome Research*, **2017**, 27, 1112-1125	9.7	100
180	Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. *Cancer Research*, **2017**, 77, 2903-2913	10.1	77
179	RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2017**, 13, 1183-1193	6	46
178	Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer. *Clinical Cancer Research*, **2017**, 23, 5611-5621	12.9	39
177	Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. *Gynecologic Oncology*, **2017**, 146, 101-108	4.9	24
176	Endothelial cell malignancies: new insights from the laboratory and clinic. *Npj Precision Oncology*, **2017**, 1, 11	9.8	20
175	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	7
174	Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. *Oncology Letters*, **2017**, 14, 2869-2877	2.6	6
173	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. *Oncotarget*, **2017**, 8, 96496-96505	3.3	39

172	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. *Clinical Cancer Research*, **2017**, 23, 7034-7046	12.9	52
171	Immune cell profiling in cancer: molecular approaches to cell-specific identification. *Npj Precision Oncology*, **2017**, 1, 26	9.8	42
170	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. *Nature Communications*, **2017**, 8, 310	17.4	112
169	Platelet "first responders" in wound response, cancer, and metastasis. *Cancer and Metastasis Reviews*, **2017**, 36, 199-213	9.6	98
168	Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. *Psychoneuroendocrinology*, **2017**, 84, 139-142	5	28
167	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. *Gynecologic Oncology*, **2017**, 147, 41-46	4.9	13
166	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. *Cell Reports*, **2017**, 21, 2785-2795	10.6	23
165	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. *Science Translational Medicine*, **2017**, 9,	17.5	62
164	DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. *Carcinogenesis*, **2017**, 38, 797-805	4.6	14
163	Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. *Molecular Therapy - Nucleic Acids*, **2017**, 9, 251-262	10.7	44
162	PRKCI promotes immune suppression in ovarian cancer. *Genes and Development*, **2017**, 31, 1109-1121	12.6	43
161	A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. *Platelets*, **2017**, 28, 99-102	3.6	11
160	MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. *Journal of Pathology*, **2017**, 241, 67-79	9.4	8
159	Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. *Fertility and Sterility*, **2017**, 107, 457-466.e9	4.8	21
158	ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. *Oncotarget*, **2017**, 8, 88410-88420	3.3	6
157	Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. *Oncotarget*, **2017**, 8, 27380-27392	3.3	9
156	Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. *Oncotarget*, **2017**, 8, 69047-69061	3.3	
155	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. *Cancer Cell*, **2016**, 30, 273-289	24.3	92

154	Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. *Journal of Medical Imaging*, **2016**, 3, 036001	2.6	21
153	MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. *Journal of Hematology and Oncology*, **2016**, 9, 112	22.4	12
152	Association of Ovarian Tumor β-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1587-1594	4	14
151	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. *Molecular Cancer Therapeutics*, **2016**, 15, 2894-2904	6.1	30
150	The rise of genomic profiling in ovarian cancer. *Expert Review of Molecular Diagnostics*, **2016**, 16, 1337-1358	3.8	14
149	Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. *Cell Reports*, **2016**, 17, 1621-1631	10.1	17
148	Ovarian cancer. *Nature Reviews Disease Primers*, **2016**, 2, 16061	51.1	420
147	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. *Cancer Research*, **2016**, 76, 6320-6330	10.1	85
146	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. *Nature Communications*, **2016**, 7, 11169	17.4	83
145	Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?. *Cancer*, **2016**, 122, 325-6	6.4	3
144	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. *Cancer Research*, **2016**, 76, 3671-5	10.1	23
143	ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. *Cancer Cell*, **2016**, 29, 874-888	24.3	29
142	Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy. *Journal of Nuclear Medicine*, **2016**, 57, 1778-1783	8.9	16
141	Role of Increased n-acetylaspartate Levels in Cancer. *Journal of the National Cancer Institute*, **2016**, 108, djv426	9.7	32
140	Prediction of anti-angiogenesis escape. *Gynecologic Oncology*, **2016**, 141, 80-5	4.9	12
139	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
138	Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. *Methods in Molecular Biology*, **2016**, 1402, 189-197	1.4	8
137	Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. *Gynecologic Oncology*, **2016**, 141, 57-64	4.9	24

136	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. *Cancer Discovery*, **2016**, 6, 235-46	24.4	404
135	Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. *Molecular Cancer Therapeutics*, **2016**, 15, 618-27	6.1	22
134	Targeting the tumour microenvironment in ovarian cancer. *European Journal of Cancer*, **2016**, 56, 131-143	7.5	69
133	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. *Journal of Immunology*, **2016**, 196, 1412-8	5.3	44
132	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. *Clinical Cancer Research*, **2016**, 22, 1713-24	12.9	47
131	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. *Journal of Clinical Investigation*, **2016**, 126, 1885-96	15.9	68
130	TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. *Aging*, **2016**, 8, 3507-3519	5.6	38
129	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. *Genes and Cancer*, **2016**, 7, 60-72	2.9	28
128	NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. *Oncotarget*, **2016**, 7, 47576-47585	3.3	2
127	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. *Oncotarget*, **2016**, 7, 15093-104	3.3	49
126	Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. *Oncotarget*, **2016**, 7, 20825-39	3.3	6
125	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. *Oncotarget*, **2016**, 7, 35132-43	3.3	9
124	Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. *Methods in Molecular Biology*, **2016**, 1402, 33-41	1.4	5
123	Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. *International Journal of Nanomedicine*, **2016**, 11, 5729-5742	7.3	23
122	miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. *Oncotarget*, **2016**, 7, 25930-48	3.3	39
121	Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. *International Journal of Cancer*, **2016**, 139, 291-9	7.5	18
120	In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. *Scientific Reports*, **2016**, 6, 38348	4.9	43
119	Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. *Hepatology*, **2016**, 63, 864-79	11.2	63

118	Platelets are not hyperreactive in patients with ovarian cancer. *Platelets*, **2016**, 27, 716-718	3.6	13
117	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. *Hepatology*, **2016**, 63, 159-72	11.2	80
116	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. *Molecular Cancer Therapeutics*, **2016**, 15, 1344-52	6.1	30
115	Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. *Future Oncology*, **2016**, 12, 1439-56	3.6	47
114	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. *Cell Reports*, **2016**, 15, 1493-1504	10.6	56
113	Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. *Gynecologic Oncology*, **2016**, 141, 260-263	4.9	53
112	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. *Cancer Treatment Reviews*, **2016**, 50, 35-47	14.4	110
111	microRNA Therapeutics in Cancer - An Emerging Concept. *EBioMedicine*, **2016**, 12, 34-42	8.8	275
110	Evoking picomolar binding in RNA by a single phosphorodithioate linkage. *Nucleic Acids Research*, **2016**, 44, 8052-64	20.1	61
109	Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. *BBA Clinical*, **2016**, 6, 76-81		23
108	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. *Clinical Cancer Research*, **2015**, 21, 2127-37	12.9	49
107	A framework for a personalized surgical approach to ovarian cancer. *Nature Reviews Clinical Oncology*, **2015**, 12, 239-45	19.4	98
106	Targeting c-MYC in Platinum-Resistant Ovarian Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 2260-9	6.1	68
105	Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. *Brain, Behavior, and Immunity*, **2015**, 50, 58-62	16.6	5
104	Nanotechnology: Future of Oncotherapy. *Clinical Cancer Research*, **2015**, 21, 3121-30	12.9	54
103	Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?. *Current Anesthesiology Reports*, **2015**, 5, 250-256	1	6
102	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. *JAMA Oncology*, **2015**, 1, 486-94	13.4	27
101	TP53 loss creates therapeutic vulnerability in colorectal cancer. *Nature*, **2015**, 520, 697-701	50.4	154

100	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. *Clinical Cancer Research*, **2015**, 21, 3286-97	12.9	27
99	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 1466-1475	6.1	11
98	Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. *Gynecologic Oncology*, **2015**, 137, 553-8	4.9	56
97	Erythropoietin Stimulates Tumor Growth via EphB4. *Cancer Cell*, **2015**, 28, 610-622	24.3	60
96	Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. *Gynecologic Oncology*, **2015**, 139, 481-6	4.9	34
95	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. *Cancer Cell*, **2015**, 28, 529-540	24.3	465
94	Sympathetic nervous system regulation of the tumour microenvironment. *Nature Reviews Cancer*, **2015**, 15, 563-72	31.3	284
93	State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. *Gynecologic Oncology*, **2015**, 138, 223-6	4.9	25
92	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. *European Journal of Cancer*, **2015**, 51, 1978-88	7.5	35
91	Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 2677-86	6.1	8
90	Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 448-59	12.9	43
89	Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. *Clinical Cancer Research*, **2015**, 21, 955-61	12.9	115
88	The Role of Angiogenesis in Cancer **2015**, 64-71		4
87	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. *Npj Systems Biology and Applications*, **2015**, 1, 15001	5	3
86	Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. *Cancer*, **2015**, 121, 3444-51	6.4	129
85	Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. *Cancer*, **2015**, 121, 3543-50	6.4	10
84	Advances and Challenges of Liposome Assisted Drug Delivery. *Frontiers in Pharmacology*, **2015**, 6, 286	5.6	1103
83	Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. *PLoS ONE*, **2015**, 10, e0131095	3.7	4

82	Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. *Gynecologic Oncology*, **2015**, 138, 332-8	4.9	31
81	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	80
80	Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 14266-71	11.5	41
79	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. *Cell Reports*, **2015**, 13, 2395-2402	10.6	75
78	STAMP2 increases oxidative stress and is critical for prostate cancer. *EMBO Molecular Medicine*, **2015**, 7, 315-31	12	37
77	Preclinical and clinical development of siRNA-based therapeutics. *Advanced Drug Delivery Reviews*, **2015**, 87, 108-19	18.5	313
76	Differential platelet levels affect response to taxane-based therapy in ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 602-10	12.9	56
75	Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. *Gynecologic Oncology*, **2015**, 136, 198-204	4.9	12
74	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. *Nature Cell Biology*, **2015**, 17, 311-21	23.4	155
73	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. *PLoS ONE*, **2015**, 10, e0131833	3.7	18
72	Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. *Oncotarget*, **2015**, 6, 4266-73	3.3	56
71	Platelet Function in Ovarian Cancer. *Blood*, **2015**, 126, 4656-4656	2.2	
70	Notch3 pathway alterations in ovarian cancer. *Cancer Research*, **2014**, 74, 3282-93	10.1	51
69	Platelets and cancer: a casual or causal relationship: revisited. *Cancer and Metastasis Reviews*, **2014**, 33, 231-69	9.6	195
68	Liposomal siRNA nanocarriers for cancer therapy. *Advanced Drug Delivery Reviews*, **2014**, 66, 110-6	18.5	274
67	Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	124
66	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. *Nature Communications*, **2014**, 5, 5202	17.4	130
65	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. *Nature Communications*, **2014**, 5, 5203	17.4	164

64	2ꞌOMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. *Nature Communications*, **2014**, 5, 3459	17.4	81
63	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. *Nature Communications*, **2014**, 5, 5092	17.4	79
62	Therapeutic silencing of KRAS using systemically delivered siRNAs. *Molecular Cancer Therapeutics*, **2014**, 13, 2876-85	6.1	59
61	Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. *Molecular Cancer Therapeutics*, **2014**, 13, 2583-94	6.1	21
60	Hematogenous metastasis of ovarian cancer: rethinking mode of spread. *Cancer Cell*, **2014**, 26, 77-91	24.3	203
59	Convergence of nanotechnology and cancer prevention: are we there yet?. *Cancer Prevention Research*, **2014**, 7, 973-92	3.2	9
58	Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. *Cancer Letters*, **2014**, 352, 97-101	9.9	30
57	Definition of PKC-, CDK6, and MET as therapeutic targets in triple-negative breast cancer. *Cancer Research*, **2014**, 74, 4822-35	10.1	48
56	Autocrine effects of tumor-derived complement. *Cell Reports*, **2014**, 6, 1085-1095	10.6	118
55	Platelet effects on ovarian cancer. *Seminars in Oncology*, **2014**, 41, 378-84	5.5	40
54	Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. *Cell Reports*, **2014**, 7, 488-500	10.6	38
53	Platelet-derived growth factor receptor alpha (PDGFR) targeting and relevant biomarkers in ovarian carcinoma. *Gynecologic Oncology*, **2014**, 132, 166-75	4.9	26
52	miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. *Nature*, **2014**, 512, 431-5	50.4	276
51	BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. *Molecular Oncology*, **2014**, 8, 1429-40	7.9	26
50	Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. *Cancer Biology and Therapy*, **2014**, 15, 919-29	4.6	33
49	RNAi therapies: drugging the undruggable. *Science Translational Medicine*, **2014**, 6, 240ps7	17.5	176
48	MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. *Oncology Reports*, **2014**, 31, 2021-8	3.5	65
47	The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. *Cell Reports*, **2014**, 8, 1447-60	10.6	71

46	Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. *Cancer Cell*, **2014**, 26, 863-879	24.3	34
45	miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. *Nature Communications*, **2014**, 5, 5671	17.4	125
44	Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. *Clinical Cancer Research*, **2014**, 20, 3280-8	12.9	55
43	Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. *Journal of Ovarian Research*, **2014**, 7, 109	5.5	27
42	Biologic effects of platelet-derived growth factor receptor blockade in uterine cancer. *Clinical Cancer Research*, **2014**, 20, 2740-50	12.9	13
41	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. *Cancer Biology and Therapy*, **2014**, 15, 1061-7	4.6	27
40	Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 1750-7	6.1	23
39	Perioperative beta-blocker use and survival in lung cancer patients. *Journal of Clinical Anesthesia*, **2014**, 26, 106-17	1.9	35
38	Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. *Gynecologic Oncology*, **2014**, 133, 473-9	4.9	44
37	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. *Anticancer Research*, **2014**, 34, 811-817	2.3	46
36	Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. *Cancer Discovery*, **2013**, 3, 1302-15	24.4	123
35	Tumour angiogenesis regulation by the miR-200 family. *Nature Communications*, **2013**, 4, 2427	17.4	295
34	Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. *Cancer Cell*, **2013**, 23, 186-99	24.3	305
33	Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. *Gynecologic Oncology*, **2013**, 128, 344-8	4.9	38
32	RNAi in Cancer Therapy **2013**, 271-307		
31	Platelets increase the proliferation of ovarian cancer cells. *Blood*, **2012**, 120, 4869-72	2.2	157
30	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	13.2	2783
29	Paraneoplastic thrombocytosis in ovarian cancer. *New England Journal of Medicine*, **2012**, 366, 610-8	59.2	505

28	Social influences on clinical outcomes of patients with ovarian cancer. *Journal of Clinical Oncology*, **2012**, 30, 2885-90	2.2	119
27	Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. *Brain, Behavior, and Immunity*, **2011**, 25, 250-5	16.6	128
26	Stress influences on anoikis. *Cancer Prevention Research*, **2011**, 4, 481-5	3.2	24
25	A novel platform for detection of CK+ and CK- CTCs. *Cancer Discovery*, **2011**, 1, 580-6	24.4	162
24	Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. *Journal of Clinical Investigation*, **2010**, 120, 1515-23	15.9	192
23	Targeted gene silencing using RGD-labeled chitosan nanoparticles. *Clinical Cancer Research*, **2010**, 16, 3910-22	12.9	218
22	Regulation of tumor angiogenesis by EZH2. *Cancer Cell*, **2010**, 18, 185-97	24.3	290
21	EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. *Journal of the National Cancer Institute*, **2009**, 101, 1193-205	9.7	75
20	Dual targeting of EphA2 and FAK in ovarian carcinoma. *Cancer Biology and Therapy*, **2009**, 8, 1027-34	4.6	47
19	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. *Clinical Cancer Research*, **2009**, 15, 3770-80	12.9	103
18	Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?. *Gynecologic Oncology*, **2009**, 113, 86-90	4.9	124
17	Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. *Gynecologic Oncology*, **2009**, 114, 431-6	4.9	68
16	Functional significance of VEGFR-2 on ovarian cancer cells. *International Journal of Cancer*, **2009**, 124, 1045-53	7.5	100
15	Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. *Brain, Behavior, and Immunity*, **2009**, 23, 176-83	16.6	118
14	Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. *Clinical Cancer Research*, **2008**, 14, 6839-46	12.9	112
13	Stress hormone-mediated invasion of ovarian cancer cells. *Clinical Cancer Research*, **2006**, 12, 369-75	12.9	374
12	Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nature Medicine*, **2006**, 12, 939-44	50.5	836
11	Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation. *Obstetrics and Gynecology*, **2005**, 105, 514-8	4.9	16

10	Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. *Cancer*, **2005**, 104, 305-13	6.4	159
9	Social support, psychological distress, and natural killer cell activity in ovarian cancer. *Journal of Clinical Oncology*, **2005**, 23, 7105-13	2.2	199
8	Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. *Clinical Cancer Research*, **2005**, 11, 4923-33	12.9	74
7	Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. *Cancer Research*, **2005**, 65, 6910-8	10.1	560
6	Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. *Clinical Cancer Research*, **2004**, 10, 6080-5	12.9	15
5	Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. *American Journal of Obstetrics and Gynecology*, **2004**, 190, 899-909	6.4	84
4	Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. *American Journal of Pathology*, **2004**, 165, 1087-95	5.8	209
3	Vascular endothelial growth factor and social support in patients with ovarian carcinoma. *Cancer*, **2002**, 95, 808-15	6.4	128
2	p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. *Cancer Biology and Therapy*, **2002**, 1, 511-7	4.6	13
1	The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. *Cancer Biology and Therapy*, **2002**, 1, 661-4	4.6	79